BioSpace News Archive

Actinogen Medical Limited (ASX: ACW) today announces positive Phase 2a clinical data from its Alzheimer’s Disease (AD) biomarker study.

Bluestar Genomics, Inc. today announced it received accreditation for its clinical laboratory from the College of American Pathologists (CAP).

Novavax, Inc. will present new safety and immunogenicity data from the first Phase 1/2 COVID-Influenza Combination (CIC) dose-finding trial evaluating its CIC vaccine candidate at the World Vaccine Congress (WVC) Europe, October 11 to 14, 2022.

Sudo Biosciences today announced the appointment of Imran Babar, Ph.D., as chief business officer.

SetPoint Medical , a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, announced the enrollment of the first participant in Stage 2 of the company’s RESET-RA pivotal study.

Therapeutic Solutions International (TSOI) announced today receipt of a “Notice of Allowance” from the United States Patent and Trademark Office for its patent entitled “Neuroprotection and Neuroregeneration by Pterostilbene and Compositions Thereof.”

scPharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved FUROSCIX® (furosemide injection), a proprietary formulation of furosemide delivered via an On-Body Infusor for the treatment of congestion due to fluid overload in adults with New York Heart Association Class II/III chronic heart failure.

AB Science SA (Euronext - FR0010557264 - AB) today announces that the first authorizations have been received to initiate its phase 3 confirmatory study (AB21004) evaluating masitinib in patients with mild to moderate Alzheimer’s Disease (AD) from the French Medicine Agency (ANSM) together with AEMPS (Spain agency) and EOF (Greece agency).

Synergys Biotherapeutics, a preclinical stage biotherapeutics company developing Vasculogenic Mimicry (VM)-blocking antibody fusion drugs, announced today that it has been awarded a Phase I/Phase II Fast-Track grant from the National Cancer Institute under the auspices of the Small Business Innovation Research (SBIR) program of the National Institutes of Health.

Aravive Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that it received a $6 million development milestone payment from its licensee, 3D Medicines Inc.